IMMVF (Immunovia AB) Institutional Ownership: 2.21% (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMMVF Immunovia AB IMMVF
43 GF Score
Price $0.02
GF Value $0.01
! 4 Warning Signs
View Full Analysis

What is Immunovia AB Institutional Ownership?

Immunovia AB IMMVF -61.59% 43 Institutional Ownership is 2.21% as of Jul. 17, 2026. GuruFocus rates IMMVF with a GF Score™ of 43/100 and a GF Value™ of $0.01. The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Immunovia AB's institutional ownership is 2.21%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Immunovia AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Immunovia AB's Float Percentage Of Total Shares Outstanding is 0.00%.

Immunovia AB Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Immunovia AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunovia AB Institutional Ownership Chart

Immunovia AB Historical Data

The historical data trend for Immunovia AB can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 2.19 1.99 9.98 3.73 3.73 3.52 3.21 3.34 3.34 3.52
IMMVF
43GF Score
Immunovia AB IMMVF
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunovia AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 2.21% mean?
Immunovia AB (IMMVF) has a Institutional Ownership of 2.21% as of Jul. 17, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Immunovia AB and its competitors.
Is Immunovia AB's Institutional Ownership too high?
Immunovia AB's current Institutional Ownership is 2.21%. Overall, Immunovia AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Immunovia AB's Institutional Ownership compare to TMO and DHR?
Immunovia AB's Institutional Ownership of 2.21% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Medical Diagnostics & Research company?
A good Institutional Ownership depends on the Medical Diagnostics & Research industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Immunovia AB and its competitors. Immunovia AB's current Institutional Ownership is 2.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovia AB stock overvalued right now?
Immunovia AB (IMMVF) has a current Institutional Ownership of 2.21%. The stock's GF Value™ is $0.01, compared to a current price of $0.02 — trading 100% above its estimated fair value. The current Institutional Ownership is 2.21%. Immunovia AB's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Immunovia AB (IMMVF), the current Institutional Ownership is 2.21% as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immunovia AB (IMMVF) Overvalued in 2026?

Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued. The current stock price of $0.02 is trading 100% above its estimated GF Value™ of $0.01.

Key valuation signals for IMMVF:

  • Institutional Ownership: 2.21%
  • GF Value™: $0.01 vs. price of $0.02 (100% above fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the IMMVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunovia AB Business Description

Other Exchanges IMMNOV:Sweden0G8X:UK
Address Scheelevagen 8, Medicon Village, Lund, SWE, 223 63
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
43GF Score

Get the complete analysis for IMMVF

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price
$0.01
GF Value